首页>
外国专利>
Use of Levosimendan to Treat Left Ventricular Systolic Dysfunction in Patients Undergoing Cardiac Surgery Requiring Cardiopulmonary Bypass
Use of Levosimendan to Treat Left Ventricular Systolic Dysfunction in Patients Undergoing Cardiac Surgery Requiring Cardiopulmonary Bypass
展开▼
机译：左西孟旦在接受心脏外科手术而需要体外循环的患者中的左心室收缩功能障碍的治疗
展开▼
页面导航
摘要
著录项
相似文献
摘要
Methods of (i) reducing morbidity and/or mortality in a human patient undergoing cardiac surgery; (ii) preventing, or reducing the risk of development of, LCOS in a human patient undergoing cardiac surgery; or (iii) reducing the risk of, intensity of, or occurrence of, one or more postoperative adverse events in a human patient undergoing cardiac surgery. The methods can involve (a) a first period of administering to the patient levosimendan for about 1 hour, in which the administration of levosimendan during the first period is initiated: (i) before skin incision for the cardiac surgery, and (ii) at an infusion dose of about 0.2 μg/kg/min; and (b) a second period of administering to the patient levosimendan for about 23 hours, in which the administration of levosimendan during the second period is initiated at an infusion dose of about 0.1 μg/kg/min.
展开▼
机译：（i）降低接受心脏手术的人类患者的发病率和/或死亡率的方法; （ii）在进行心脏手术的人类患者中预防或降低LCOS的发展; （iii）降低接受心脏手术的人类患者发生一种或多种术后不良事件的风险，强度或发生率。所述方法可涉及（a）对患者左西孟旦给药的第一阶段，持续约1小时，其中在第一阶段中开始左西孟旦的给药：（i）在心脏手术的皮肤切口之前，和（ii）输注剂量约为0.2μg/ kg / min; （b）向患者左西孟旦施用约23小时的第二阶段，其中在第二阶段中以约0.1μg/ kg / min的输注剂量开始左西孟旦的施用。
展开▼
